Shares of Bausch Health (NYSE:BHC) dropped about 8% in early trading on Friday after the company disclosed unsuccessful ...

Abstract Background Hepatic encephalopathy is a chronically debilitating complication of hepatic cirrhosis. The efficacy of rifaximin, a minimally absorbed antibiotic, is well documented in the ...

Branched-chain amino acids (BCAAs) may also be used as part of treatment, but they work in a different way. People with cirrhosis often have low levels of BCAAs. Taking BCAA supplements can help ...

Investing.com -- Bausch Health (NYSE:BHC) stock plunged 8% Friday morning after the company announced disappointing results ...

The condition is associated with high morbidity and mortality. The drug treatment rifaximin is commonly used to treat hepatic encephalopathy, yet treatment retention remains low. Our research ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Fewer patients treated with rifaximin had an overt ...

MINNEAPOLIS/ST. PAUL (08/24/2023) — Researchers from the University of Minnesota Medical School and College of Pharmacy have found that high costs for hepatic encephalopathy treatment in patients with ...

LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (BHC), a global, diversified pharmaceutical company, and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), ...

The Hepatic Encephalopathy Market is expected to show positive growth in the forecast period (2022–2032) due to the development of well-designed, randomized, controlled non-crossover trials with ...

Trial News Online has published an article examining Wernicke’s encephalopathy (WE) in the context of bariatric surgery, ...